Amgen and Samsung Bioepis can continue to sell their Soliris (eculizumab) biosimilars in Europe, after the Court of Appeal of the Unified Patent Court refused originator Alexion’s request for injunctions. Alexion had sought injunctive relief based on its European patent 3,167,888,B1 covering the treatment of paroxysmal nocturnal hemoglobinuria.
Amgen’s Bekemv was the first eculizumab biosimilar to be endorsed in Europe, in early 2023, with Samsung Bioepis